1. International Agency for Research on Cancer. IARC monographs on the evaluation of the carcinogenic nsk to humans. Vol 26,1981
2. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide;Baker, G.L.; Kahl, L.E.; Zee, B.C.; Stolzer, B.L.; Agarwal, A.M.; Medsger, T.A.;Am J Med,1987
3. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer;Greene, M.H.; Boice, J.D.; Greer, B.E.; Blessing, J.A.; Dembo, A.J.;New Engl Y Med,1982
4. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide;Haas, J.F.; B, Kittelmann; WH, Mehnert;Br J Cancer,1987
5. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for NonHodgkin's disease;Pedersen-Bjergaard, J.; Ersboll, J.; Sorensen, H.M.; etve;Ann Intern Med,1985